Today’s diabetes clinical development landscape is competitive, complex, and in demand. Continuous Glucose Monitoring (CGM) has the potential to become the new gold-standard in diabetes clinical trials. CGM provides more robust glycemic data sets and glucose variability than ever before, which leads to better clinical outcomes and patient safety. Navigating and understanding the evolving regulatory landscape in this area is paramount to your trial’s success. Listen as a panel of industry experts discuss CGM technology, regulatory trends, therapeutic & industry perspectives, and how CGM can be used to develop smarter diabetes clinical trials. Our panel includes Quintiles leader Sam Osman, Vice President of Clinical Development at Lexicon Pharmaceuticals Dr. Paul Strumph, Executive Director of the International Diabetes Center (IDC) at Park Nicollet, Dr. Rich Bergenstal, and Richard Yang, VP of Corporate Sales & Connected Solutions of leading CGM manufacturer Dexcom®.
Presentation November 11, 2016